GenericPedia - Encyclopedia of Generic Drugs brand name list - GenericPedia - Encyclopedia of Generic Drugs brand name list with manufacturer name, uses of generic drugs in different disease with sign symptoms

  • Submit New Brand name, Manufacurer details - You can submit new product / Manufacturer details either by writing the details in text box below or if you do not have enough time then you can take 3 or
  • Free Online consultation with Doctor's Expert Panel - Free online medical consultation with Doctor's Expert Panel for taking right step regarding your treatment,investigation before paying huge amount
  • FDA approves Ruconest for treatment of hereditary angioedema - The U.S. Food and Drug Administration approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). RuconestRu  - RecombinantC  - COne - 1Est - esteraseInhibitor Ruconest® is the first recombinant human C1 esterase inhibitor (rhC1INH) approved for use in patients with HAE. rhC1INH and plasma-derived C1INH have an identical amino acid sequence. 18 The in vitro inhibitory potency of rhC1INH toward target enzymes is comparable with that of plasma-derived C1INH. 1, 6, 19  Ruconest® is the first recombinant human C1 esterase inhibitor (rhC1INH) developed and approved for the treatment of acute angioedema attacks in HAE patients. Use of a well-controlled transgenic platform for the production of Ruconest® ensures that product supply is virtually unlimited and avoids the risk of transmission of human blood-borne infections. Hereditary angioedema (types I, II and III) (also known as "HAE") is a rare, autosomal dominantly inherited blood disorder that causes episodic attacks of swelling that may affect the face, extremities, genitals, gastrointestinal tract and upper airways.Swellings of the intestinal mucosa may lead to vomiting and painful, colic-like intestinal spasms that may mimic intestinal obstruction. Airway edema may be life-threatening. Episodes may be triggered by trauma, surgery, dental work, menstruation, some medications, viral illness and stress; however, this is not always readily determined.This disorder affects approximately one in 10,000–50,000 people “Hereditary angioedema is a rare and potentially life-threatening disease,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval provides an important treatment option for these patients.” Ruconest is a human recombinant C1-esterase inhibitor purified from the milk of genetically modified (transgenic) rabbits. Ruconest is intended to restore the level of functional C1-esterase inhibitor in a patient’s plasma, thereby treating the acute attack of swelling.   The safety and efficacy of Ruconest was evaluated in a multicenter controlled clinical trial. Forty-four adult and adolescent patients with acute attacks were treated with Ruconest. The most common adverse reactions reported in patients treated with Ruconest were headache, nausea and diarrhea. Ruconest received orphan-drug designation for acute attacks by the FDA because it is intended for treatment of a rare disease or condition. Ruconest is manufactured by Pharming Group NV, Leiden, the Netherlands, and will be distributed in the United States by Santarus Inc., a wholly owned subsidiary of Salix Pharmaceuticals Inc., Raleigh, North Carolina. The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
  • FDA recommend against aspirin to prevent First Heart Attacks - aspirin should not be used in primary prevention of heart attack as per recent recommendations by FDA,but can be used in secondary prevention, bleeding risk
  • FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma - The U.S. Food and Drug Administration approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs ( relapsed and refractory multiple myeloma ). Pomalidomide (marketed as Pomalyst by Celgene), is a derivative of thalidomide that is anti-angiogenic and also acts as an immunomodulator.3-amino-thalidomide ( Pomalidomide ) was able to directly inhibit both the tumor cell and vascular compartments of myeloma cancers. This dual activity of pomalidomide makes it more efficacious than thalidomide in vitro and in vivo. Pomalidomide directly inhibits angiogenesis and myeloma cell growth. This dual effect is central to it's activity in myeloma, rather than other pathways such as TNF alpha inhibition, since potent TNF alpha inhibitors including rolipram and pentoxifylline do not inhibit myeloma cell growth nor angiogenesis. Up regulation of Interferon gamma, IL-2 and IL-10 as well as down regulation of IL-6 have been reported for pomalidomide. These changes may contribute to pomalidomide's anti-angiogenic and anti-myeloma activities. It is intended for patients who have received at least two prior therapies, including lenalidomide and bortezomib, and whose disease did not respond to treatment and progressed within 60 days of the last treatment (relapsed and refractory). Multiple myeloma is a form of blood cancer that primarily affects older adults and arises from plasma cells in the bone marrow. “Pomalyst is the third drug in a class of immunomodulatory agents that includes lenalidomide and thalidomide, and is the second drug approved in the past year to treat multiple myeloma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research. “Treatment for multiple myeloma is tailored to meet individual patient’s needs, and today’s approval provides an additional treatment option for patients who have not responded to other drugs.” In July 2012, FDA approved Kyprolis (carfilzomib) to treat multiple myeloma. Pomalyst’s safety and effectiveness was evaluated in a clinical trial of 221 patients with relapsed or refractory multiple myeloma. The trial was designed to measure the number of patients whose cancer completely or partially disappeared after treatment (objective response rate, or ORR). Patients were randomly assigned to receive Pomalyst alone or Pomalyst with low-dose dexamethasone, a corticosteroid. Results showed 7.4 percent of patients treated with Pomalyst alone achieved ORR. The median duration of response has not yet been reached in these patients. In patients treated with Pomalyst plus low-dose dexamethasone, 29.2 percent achieved ORR with a 7.4-month median duration of response. Pomalyst, lenalidomide and thalidomide are marketed by Celgene, based in Summit, N.J. Kyprolis is marketed by South San Francisco, Calif.-based Onyx Pharmaceuticals. Pomalyst was also granted orphan product designation because it is aimed at a rare disease/condition. A Boxed Warning for Pomalyst (pomalidomide) A Boxed Warning contained in the Pomalyst packaging alerts doctors and patients that the medication must not be given to pregnant mothers because of the serious risk of life-threatening birth defects (Pomalyst is an analogue of thalidomide), as well as increasing the possibility of blood clots. Because of Pomalyst’s embryo-fetal risk, it is available only through the Pomalyst Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribers must be certified with the Pomalyst REMS Program by enrolling and complying with the REMS requirements. Patients must sign a Patient-Physician agreement form and comply with the REMS requirements. In particular, female patients who are not pregnant but can become pregnant must comply with the pregnancy testing and contraception requirements, and males must comply with contraception requirements. Pharmacies must be certified with the Pomalyst REMS Program, must only dispense to patients who are authorized to receive the drug and must comply with REMS requirements. Both lenalidomide and thalidomide have similar REMS. Common side effects include a decrease in infection-fighting white blood cells (neutropenia), fatigue and weakness, low red blood cell count (anemia), constipation, diarrhea, low levels of platelets in the blood (thrombocytopenia), upper respiratory tract infections, back pain and fever.
  • FDA approves three new drug treatments for type 2 diabetes - Alogliptin (codenamed SYR-322, trade name Nesina) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, developed by Takeda Pharmaceutical
  • Long-term consequences of vaginal delivery on the pelvic floor - Women are more likely to experience urinary incontinence, prolapse and faecal incontinence 20 years after one vaginal delivery rather than one caesarean section, finds new research published in a thesis from Sahlgrenska Academy. Urinary incontinence, prolapse and faecal incontinence are common conditions affecting adult women of all ages and can have a negative influence on quality of life. Study on risk factors This unique study, performed by researcher Maria Gyhagen at the Sahlgrenska Academy, looked at the prevalence and risk factors for urinary incontinence, prolapse and faecal incontinence 20 years after vaginal delivery or caesarean section. The SWEPOP (Swedish pregnancy, obesity and pelvic floor) study was conducted in 2008 and data was obtained from the Medical Birth Register about women who had delivered only one child between 1985-1988 and had no further children. A questionnaire was sent to the women in 2008 and 6, 148 completed it answering questions on height, weight, urinary or faecal incontinence, genital prolapse, menstrual status, hysterectomy, the menopause and hormone treatment. Associated with 275% higher risk Two decades after one childbirth, vaginal delivery was associated with a 67% increased odds of urine incontinence (UI), and UI being present more than 10 years later increased by 275% compared to caesarean section. - Current BMI was the most important BMI-determinant for UI, which is important, since BMI is modifiable, says Maria Gyhagen.  Symptomatic prolapse The single most important risk factor for symptomatic prolapse was delivery via the vaginal route. Birthweight above 4500g was a risk factor for symptomatic prolapse after vaginal delivery. Symptomatic prolapse was also an important risk factor for urine incontinence. Higher prevalence of faecal incontinence The prevalence of faecal incontinence was higher after vaginal delivery compared with caesarean section. Perineal tear of the 2nd degree almost doubled the prevalence of faecal incontinence. Episiotomy was protective against late faecal incontinence. The prevalence of urinary incontinence, prolapse and faecal incontinence did not differ between women delivered by acute compared to elective caesarean section, indicating that it is not until the fetus passes through the delivery canal that the injuries occur that causes these pelvic floor disorders. First study of its kind This is the first study of its kind to show that one vaginal delivery influences the long-term risk of developimg urinary incontinence, prolapse and faecal incontinence compared to one caesarean section. The results of this study provide important new information for women who are concerned that a vaginal delivery will lead to long-term pelvic floor damage. However it is important to note that when choosing the most suitable form of delivery it is necessary to consider numerous medical issues that can potentially influence the health of the mother and child. The thesis Long-term consequences of vaginal delivery on the pelvic floor. A comparison with caesarean section in one-para women was defended by Maira Gyhagen on January 25, 2013.
  • Privacy Policy - Your Privacy Your privacy is important to us. To better protect your privacy we provide this notice explaining our online information practices and the cho
  • Disclaimer - Information on this Site may contain technical inaccuracies or typographical errors. Information may be changed or updated without notice.

    Country:, North America, US

    City: -122.3933 California, United States

  • Patrice Holman - Omea XL

    It's a scam. I overpaid for a product that does not ease my pain from arthritis, I spent 49.98 for pills that were overpriced. Larry King does not take Omega XL. If he did he he couldn.t possably promote this drug.. I will warn my family and friends not to waste their money for Omega XL. [email protected].

  • B Johnson - Great for women tired of pads and tampons

    I cant quite get the cup to stay put, but i will continue trying. What function i did experiemce was good. Many women suggest wearing a pad while youre adjusting/learning how to use this. I agree. Also, be mindful of when youll need to change it and whether or not youll have enough privacy to access a sink to clean your hands before inserting a new one. Something that worked for me was keeping a glove in my purse (latex or otherwise), and using it to retrieve the old one and insert the new one...afterward i dispose of the glove, the cup, and i can leave the stall with relatively clean hands to wash at the communal sinks. Definitely worth the try if youre someone who cares about the potential dangers of modern day pads and tampons, and the impact they have not only on your body but the environment. Great way to decide whether or not you want to invest in a reusable cup.

  • Kindle Customer - Disappointed

    What bothered me most was the way it ended. The story did not end. You know another book will be written so that you can pay another 15 bucks to find out how it all finally ends.

  • J Jhu - I absolutely love this product BUT I would never ever

    I absolutely love this product BUT I would never ever, ever think of buying it on amazon. There arre too many fakes online with dangerous chemicals in it. and you're only supposed to get it frrom a registered distrributor, per company agreement. So what this stuff may be, or how old it is, is questionable. Would you buy your newborrn's life saving medicine frrorm amazon?

  • M. Mao - The tube is not much different from toothpaste tube, ...

    The tube is not much different from toothpaste tube, doesn't prevent leaking at all. The product actually arrived soaked.

  • Yumi Yuan - Missing preorder dlc

    Game is great, however, I preordered the game and was suppose to get the Brothers in Arms dlc, but no sign of it anywhere. I got a code to redeem the the game, but no code to unlock the character and weapon skins.